Obesity Management in 2026: Beyond Weight Loss

The Expanding Role of GLP-1 Receptor Agonists and Dual/Triple Incretin Therapy

SECTION 1: Introduction / Changing Concept of Obesity

1.1 The Old Paradigm: "A Matter of Willpower"

1.2 The Paradigm Shift: Obesity as a Chronic, Relapsing Neurobiological Disease

1.3 Adiposity-Based Chronic Disease (ABCD): A New Diagnostic Framework

1. Defines what we are treating: Abnormalities in the mass, distribution, or function of adipose tissue (not merely body weight or BMI).
2. Defines why we are treating it: As a chronic disease with complications that confer morbidity, mortality, and impaired quality of life.

Fig. 6-7: ABCD as a diagnostic term for obesity. Fuster and Hurst's The Heart, 15th Edition.

• Biomechanical complications: Due to excess adipose tissue mass - obstructive sleep apnea (OSA), osteoarthritis, stress urinary incontinence, GERD.
• Cardiometabolic complications (CMD): Due to abnormal distribution and function of adipose tissue - T2D, dyslipidemia, hypertension, atherosclerotic cardiovascular disease (ASCVD), non-alcoholic/metabolic steatohepatitis (MASH), polycystic ovary syndrome (PCOS), chronic kidney disease.

1.4 The Expanded Goals of Obesity Treatment in 2026

• Remission of T2D
• Reduction in MACE (major adverse cardiovascular events)
• Reversal of MASH/hepatic fibrosis
• Resolution of OSA
• Slowing of CKD progression
• Improved quality of life, mobility, and mental health

SECTION 2: Pathophysiology of Obesity / Why Lifestyle Therapy Alone Fails

2.1 The Central Nervous System Architecture of Energy Balance

Energy balance regulatory circuitry. Afferent signals (leptin from fat, PYY/GLP-1 from gut L-cells, GIP from gut K-cells, ghrelin from stomach) converge on arcuate nucleus POMC/CART and NPY/AgRP neurons. - Robbins, Cotran & Kumar Pathologic Basis of Disease

2.2 Key Peripheral Hormones in Energy Regulation

Leptin

• Source: Adipocytes; output is proportional to fat stores.
• Action: Crosses blood-brain barrier to stimulate POMC/CART (appetite-suppressing) neurons and inhibit NPY/AgRP (appetite-promoting) neurons. Also stimulates thermogenesis via sympathetic innervation of adipose tissue.
• In obesity: Despite high circulating leptin levels (proportional to fat mass), leptin resistance develops. This is believed to result from hypothalamic microglial inflammation triggered by excess free fatty acids crossing the blood-brain barrier, impairing leptin receptor signaling. The result: obese individuals have high leptin yet cannot use it to suppress appetite. - Robbins & Kumar Basic Pathology, p. 421-423
• Clinical implication: Injecting leptin into obese humans fails to reduce appetite or body weight - dashing early hopes for leptin therapy.

Ghrelin

• Source: Gastric parietal cells.
• The only known gut hormone that increases food intake (orexigenic).
• Activates NPY/AgRP neurons; levels rise pre-meal and fall 1-2 hours postprandially. Importantly, this post-meal drop is attenuated in obese individuals, prolonging the hunger drive. After bariatric surgery (gastric bypass), ghrelin levels fall dramatically - a mechanism partly responsible for surgery's effectiveness beyond mere restriction.

GLP-1 (Glucagon-Like Peptide-1)

• Source: L-cells of the distal ileum and colon; released after food intake.
• Actions:
  • Pancreatic: Glucose-dependent insulin secretion from β-cells; glucagon suppression from α-cells.
  • Gastric: Slows gastric emptying → promotes satiety.
  • Hypothalamic: Acts via sensory afferents and direct brain GLP-1 receptors to stimulate POMC/CART neurons, suppress NPY/AgRP neurons → reduces food intake and caloric consumption.
  • Extra-metabolic: Cardioprotective (reduces MACE), anti-inflammatory, renoprotective, hepatoprotective.
• In obesity: GLP-1 secretion may be impaired, and the hypothalamic response to GLP-1 signals can be blunted by obesity-associated neuroinflammation. This creates a therapeutic window for pharmacological GLP-1 receptor agonism at supraphysiologic doses. - Guyton and Hall Medical Physiology, p. 877-878

GIP (Glucose-Dependent Insulinotropic Polypeptide)

• Source: K-cells of the duodenum and jejunum.
• Primary role: Potentiates glucose-stimulated insulin release (incretin effect).
• In obesity: GIP's role is paradoxical. In obese/T2D states, the direct GIP receptor pathway in hypothalamus becomes resistant. However, dual GLP-1/GIP receptor agonism (tirzepatide) achieves superior weight loss compared to GLP-1 agonism alone. The mechanism may involve GIP-mediated effects on adipocyte function, reduction in visceral fat, and synergistic CNS satiety signaling. - Guyton and Hall Medical Physiology, p. 895

PYY (Peptide YY)

• Source: L-cells (same as GLP-1); released postprandially.
• Acts centrally to inhibit NPY/AgRP neurons → reduces appetite. PYY levels are lower in obese individuals at baseline.

2.3 Adipose Tissue Dysfunction: The Engine of Metabolic Complications

2.4 Genetic and Neurological Underpinnings

• Monogenic obesity: Loss-of-function mutations in leptin, leptin receptor, POMC, PCSK1, MC4R gene - the last found in 4-5% of patients with massive obesity. These directly impair the hypothalamic satiety circuit.
• Polygenic obesity: Hundreds of common variants each contribute small effects; these interact with obesogenic environments (high caloric density food, sedentary behavior, sleep disruption, stress).
• Prader-Willi syndrome: Deletion of chromosome 15q causing extreme hyperphagia from hypothalamic dysfunction - the archetypal model of neurogenic obesity.
• Neurogenic abnormalities: Hypothalamic lesions, tumors compressing the ventromedial nucleus, and functional dysregulation of feeding circuits all cause obesity independent of caloric intake.

2.5 Why Lifestyle Therapy Alone Fails: The Adaptations Against Weight Loss

2.6 The Insulin Resistance-Adiposity Loop

• Visceral fat expands asymmetrically → more FFA → worsens insulin resistance → β-cells overwork → eventual T2D
• Insulin resistance + elevated FFA → hepatic de novo lipogenesis → MASH → cirrhosis
• Chronic hyperinsulinemia + dyslipidemia → accelerated atherosclerosis → ASCVD

SECTION 3: Recent Advances (2025-2026) / Evolution of Anti-Obesity Drugs

3.1 Historical Context: The Drug Development Timeline

3.2 GLP-1 Receptor Agonists: The First Transformation

Mechanism of Action (Detailed)

• β-cells: Glucose-dependent ↑ insulin secretion (self-limiting - no hypoglycemia at euglycemia)
• α-cells: ↓ glucagon secretion
• β-cell preservation: May reduce apoptosis and promote β-cell neogenesis

• Hypothalamic arcuate nucleus: Activates POMC/CART → suppresses appetite
• Inhibits NPY/AgRP neurons
• Vagal afferents relay GLP-1 signals from gut to nucleus tractus solitarius (NTS) in brainstem → satiety
• Reduces hedonic (reward-based) eating by modulating mesolimbic dopamine circuits (nucleus accumbens, ventral tegmental area)
• Area postrema (circumventricular organ): Directly senses circulating GLP-1, contributes to nausea at high doses

• Slows gastric emptying → prolonged satiety, reduced postprandial glucose excursions
• Reduces gastrointestinal motility (explains nausea/vomiting/constipation side effects)

• Direct cardiac GLP-1R: Modest chronotropy, improved left ventricular function
• Anti-atherosclerotic: Reduced endothelial inflammation, improved lipid profile
• Blood pressure lowering (mild)
• The SELECT trial (NEJM 2023, Lancet 2024 HF sub-analysis): Semaglutide 2.4 mg reduced MACE by 20% (HR 0.80) in 17,604 patients with established CVD and obesity - the first time an obesity drug had proven cardiovascular outcome benefit independent of T2D. In those with coexistent heart failure, semaglutide reduced MACE (HR 0.72), composite HF outcomes (HR 0.79), and cardiovascular death (HR 0.76). - Deanfield et al., Lancet 2024, PMID 39181597

• Reduces glomerular hyperfiltration, albuminuria, inflammatory pathways in podocytes
• GLP-1R expression in tubular cells: Reduces oxidative stress and inflammation

• Reduces hepatic steatosis, de novo lipogenesis
• Weight-loss mediated and possibly direct anti-inflammatory effects on hepatic stellate cells (being studied in MASH trials)

Semaglutide 2.4 mg (Wegovy) - The Reference Standard

• STEP 1 trial: 68-week treatment → -14.9% mean body weight vs -2.4% placebo (68% achieved ≥5% weight loss)
• STEP 10 trial (Lancet Diabetes Endocrinol 2024): Semaglutide 2.4 mg in patients with obesity and prediabetes → -15.3% weight loss; critically, 79.7% of participants had normoglycemia at 68 weeks vs 27.5% placebo. This suggests GLP-1 RA therapy may prevent T2D at a population scale. - McGowan et al., Lancet Diabetes Endocrinol 2024, PMID 39089293
• A 2025 systematic review and meta-analysis confirmed semaglutide's favorable cardiovascular safety and outcome profile.

3.3 Tirzepatide (Zepbound/Mounjaro) - The Second Transformation: GLP-1 + GIP Dual Agonism

Why GIP Addition Matters

• GIP reduces GLP-1R agonist-associated nausea, improving tolerability
• GIP has direct effects on adipocyte lipolysis and fat distribution - promotes fat oxidation, reduces visceral adiposity
• GIP receptors in the CNS (hippocampus, hypothalamus) may complement GLP-1 satiety pathways
• The combination achieves "synergistic" weight loss far beyond either alone

Clinical Data (SURMOUNT Program + Meta-Analysis)

• Tirzepatide 5 mg: -8.07% body weight vs placebo
• Tirzepatide 10 mg: -10.79%
• Tirzepatide 15 mg: -11.83% (absolute: -11.5 kg)
• In non-diabetic patients (SURMOUNT-1): up to 22.5% mean weight loss at 72 weeks; 36.2% achieved ≥25% weight loss at highest dose

• GLP-1 RAs reduce total body weight (-3.55 kg), fat mass (-2.95 kg), and lean mass (-0.86 kg)
• Lean mass loss constitutes ~25% of total weight lost - raising sarcopenia concerns
• Tirzepatide 15 mg achieved the greatest fat mass reduction but also among the greatest lean mass reduction
• Important clinical implication: concurrent resistance exercise training is now recommended to mitigate lean mass loss during incretin therapy

Non-Weight Cardiometabolic Benefits of Tirzepatide (2025-2026)

• SURPASS-CVOT (2026): Tirzepatide significantly reduced major kidney events compared to dulaglutide in T2D - the first kidney outcome benefit demonstrated for a dual incretin
• OSA improvement: Clinical trials show improvement in AHI (apnea-hypopnea index) with tirzepatide, independent of weight loss
• MASH: Dedicated trials showing histological improvement in hepatic steatosis and fibrosis

3.4 The 2025-2026 Frontier: Drugs That Are Rewriting What Is Medically Achievable

A. CagriSema (Semaglutide + Cagrilintide) - GLP-1 + Amylin Dual Agonism

• Semaglutide (GLP-1 RA): Central appetite suppression, satiety, slowed gastric emptying
• Cagrilintide (long-acting amylin analog): Amylin is a peptide co-secreted with insulin from β-cells. It promotes satiety via area postrema, reduces glucagon, slows gastric emptying. Amylin and GLP-1 act on complementary, non-overlapping pathways in the brainstem and hypothalamus - providing additive and potentially synergistic satiety.

• ~20-23% average weight loss at 68 weeks
• Over 40% of participants lost ≥25% body weight - approaching bariatric surgery outcomes
• Favorable metabolic profile with significant glycemic benefit
• FDA submission filed: December 2025
• Potential approval: Late 2026 / Early 2027

B. Retatrutide - Triple Receptor Agonism (GLP-1 + GIP + Glucagon): The Paradigm Redefiner

• Stimulates hepatic glycogenolysis and gluconeogenesis (raises basal metabolic rate)
• Activates brown adipose tissue (BAT) thermogenesis
• Promotes hepatic fatty acid β-oxidation (anti-steatotic)
• Increases ureagenesis (protein turnover signaling)

• 96 mg dose: -24.2% body weight at 48 weeks (non-diabetic patients with obesity) - highest weight loss ever reported in a pharmacological obesity trial at that time

• 4 trials, >5,800 participants
• Enrolling: obesity/weight management, OSA, knee osteoarthritis, cardiovascular outcomes
• TRANSCEND trial (weight management, Phase 3, presented ADA 2026 Scientific Sessions):
  • Primary outcome: weight change at 80 weeks
  • ~20% weight loss in intent-to-treat; >30% weight loss in the per-protocol (on-drug) extension arm at 104 weeks - fully in the bariatric surgery range
• TRANSCEND-T2D: Robust HbA1c reduction of ~2.0% - comparable to semaglutide and tirzepatide T2D trials
• A 2025 systematic review and network meta-analysis (Yan et al., Acta Diabetologica) confirmed retatrutide achieved greatest weight reduction among all agents, while tirzepatide showed greater glycemic control
• Potential FDA submission: Late 2026 - Early 2027

C. Oral Small-Molecule GLP-1 Receptor Agonists: Democratizing Access

• The first approved oral GLP-1 RA (at 7/14 mg for T2D)
• The 50 mg dose for obesity completed Phase 3: -15.1% body weight at 68 weeks - nearly equivalent to injectable semaglutide
• Requires fasting administration, specific absorption conditions (sodium N-[8-(2-hydroxybenzoyl)aminocaprylate] - SNAC carrier)

• A small-molecule, nonpeptide, oral GLP-1 RA - not a peptide and does not require fasting
• Phase 3 (3,127 patients, 72 weeks, PMID 40960239 - NEJM 2025):
  • Orforglipron 6 mg: -7.5% body weight vs -2.1% placebo
  • Orforglipron 12 mg: -8.4%
  • Orforglipron 36 mg: -11.2% (54.6% achieved ≥10% loss; 18.4% achieved ≥20%)
  • Significant improvements in waist circumference, systolic BP, triglycerides, non-HDL cholesterol
  • Adverse events: GI (nausea, vomiting - mostly mild/moderate), consistent with the GLP-1 RA class
• This represents a once-daily pill for obesity - potentially far more accessible than injectables, especially in lower-income countries and patients with needle phobia

• Novel once-daily oral small-molecule GLP-1 RA
• First-in-human characterization published (Haggag et al., Diabetes Obes Metab 2025, PMID 39495140)
• Phase 1/2 data showing favorable pharmacokinetics and early weight loss signals

• A "biased" agonist - selectively activates specific downstream GLP-1R signaling pathways (preferentially cAMP vs. β-arrestin pathways) to potentially achieve weight loss with reduced GI side effects
• Phase 3 (Ji et al., Lancet Diabetes Endocrinol 2025, PMID 40555243): significant weight loss in Chinese patients with overweight/obesity; positive efficacy with favorable safety profile

D. Survodutide (GLP-1 + Glucagon Dual Agonist)

• Unlike retatrutide (triple), survodutide (Boehringer Ingelheim/Zealand) is a GLP-1 + glucagon receptor dual agonist (no GIP component).
• Phase 3 results (June 2026): Two phase 3 trials confirmed weight loss with improvement in metabolic health and MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease).
• Mean weight loss: ~14.9% at 49 weeks in Phase 2.
• Particularly strong MASH/MASLD data - hepatic fat reduction and histological improvement.
• The glucagon component promotes hepatic fat oxidation - potentially making this a dual-purpose obesity + liver disease drug.

E. Amycretin - Unimolecular GLP-1 + Amylin Dual Agonist

• Where CagriSema is a combination of two separate molecules (semaglutide + cagrilintide), amycretin is a single unimolecular peptide fusing GLP-1 and amylin agonism in one molecule.
• Phase 2 data: remarkable weight loss signal (~13.1% in 12 weeks - implying projected losses exceeding any approved agent over full course)
• Phase 3 underway as of 2026
• Potential advantage: simpler manufacturing, single administration, potentially optimized receptor co-activation pharmacokinetics

F. Non-Incretin Mechanisms in the Pipeline

3.5 Comparative Efficacy: The Weight Loss Hierarchy (2026)

Retatrutide (Phase 3, on-drug)     ~30%+ at 2 years
CagriSema (Phase 3)                ~20-23%
Tirzepatide 15 mg (Phase 3)        ~22.5% (non-diabetic)
Semaglutide 2.4 mg sc (Phase 3)    ~15%
Oral semaglutide 50 mg             ~15%
Survodutide                        ~14.9%
Orforglipron 36 mg (Phase 3)       ~11.2%
Liraglutide 3 mg (Phase 3)         ~6-8%
─────────────────────────────────────────
Bariatric surgery (RYGB)           ~25-35%

3.6 Beyond Weight Loss: Organ-Specific Benefits Emerging in 2025-2026

Cardiovascular

• SELECT trial (semaglutide): 20% MACE reduction in obesity + established CVD (no T2D required)
• HF benefit: HR 0.72 for MACE in patients with coexistent HF; both HFpEF and HFrEF benefited
• SURMOUNT-CVOT (tirzepatide, 2026): Significant reduction in major kidney events vs dulaglutide; eGFR decline slowed
• Emerging: retatrutide cardiovascular outcomes trial (part of TRIUMPH program) ongoing

Obstructive Sleep Apnea (OSA)

• Tirzepatide: Phase 3 OSA trials (SURMOUNT-OSA 1 & 2) demonstrated >50% reduction in AHI
• Retatrutide OSA trial: Part of TRIUMPH program
• GLP-1 RAs appear to reduce OSA partly through fat mass reduction (pharyngeal fat), and possibly through direct respiratory neural effects

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/MASH)

• Semaglutide Phase 3 (ESSENCE trial): MASH resolution in ~62% vs 34% placebo; fibrosis improvement in ~37% vs 22%
• Survodutide: Two Phase 3 trials showing MASLD improvement (June 2026)
• GLP-1 + FGF21 (efruxifermin) combination: Phase 2 results (PMID 38447814) showing MASH resolution in 79% at 24 weeks

Chronic Kidney Disease

• GLP-1 RAs reduce urinary albumin-creatinine ratio, slow eGFR decline
• Tirzepatide: SURPASS-CVOT kidney data (2026) - first dedicated evidence
• FLOW trial (semaglutide in T2D + CKD): 24% reduction in kidney disease progression

Osteoarthritis and Musculoskeletal

• Retatrutide knee osteoarthritis trial (TRIUMPH program): Hypothesis that weight loss + possible direct anti-inflammatory effects of incretin agonism reduce joint disease

3.7 Critical Challenges and Unresolved Questions

• Concurrent resistance training protocols
• Bimagrumab (anti-ActRII) as an adjunct to preserve/build muscle during weight loss
• Optimal protein intake during incretin therapy
• Mechanick et al., Obes Rev 2025 (PMID 39295512) provides specific strategies for minimizing muscle loss during incretin-mimetic drug use.

• Thyroid C-cell tumors: Rodent signal with GLP-1 RAs (contraindicated in MEN2/medullary thyroid Ca history); human relevance unclear
• Pancreatitis: Small signal; caution in those with prior pancreatitis
• GI adverse events: Class effect - nausea, vomiting, diarrhea, constipation; usually transient; ~5-10% discontinuation rate
• Bone density effects: Under-studied, especially with profound weight loss
• Muscle quality (not just quantity): Adipose infiltration of muscle, fiber type changes - long-term functional implications unknown

3.8 Clinical Treatment Algorithm in 2026

STEP 1: Diagnose and Stage
├── Anthropometric: BMI + waist circumference + body composition
└── Clinical: Complication severity (CMD, biomechanical, psychosocial)

STEP 2: Lifestyle Therapy (ALWAYS as foundation)
├── Dietary: Caloric deficit, protein-adequate, Mediterranean/low-glycemic
├── Physical activity: 150-300 min/week moderate; resistance training (preserves muscle)
└── Behavioral: CBT, sleep optimization, stress management

STEP 3: Pharmacotherapy (based on BMI ≥30, or ≥27 + complication)
├── GLP-1 RA first line: Semaglutide 2.4 mg sc / tirzepatide 15 mg
├── Oral option: Orforglipron or oral semaglutide (access, preference)
└── Emerging (2026-27): CagriSema or retatrutide for highest-risk, highest BMI patients

STEP 4: Surgical/Procedural (BMI ≥40, or ≥35 + complications, or failed pharmacotherapy)
├── Roux-en-Y Gastric Bypass (RYGB)
├── Sleeve Gastrectomy
└── GLP-1 RA post-surgery for inadequate loss or recurrence

STEP 5: Combination (future)
└── Pharmacotherapy + bimagrumab (muscle preservation) + structured exercise

Summary Table: Key 2025-2026 Agents at a Glance

Conclusion

• Fuster and Hurst's The Heart, 15th Edition - Adiposity-Based Chronic Disease, p. 266-277
• Robbins, Cotran & Kumar Pathologic Basis of Disease - Energy Balance Circuitry, p. 421-423
• Guyton and Hall Textbook of Medical Physiology - Obesity, GLP-1, Metabolic Adaptation, p. 875-878
• Sabiston Textbook of Surgery, 7th Edition - GLP-1 RAs in Surgical Practice
• Lippincott Illustrated Reviews: Pharmacology - Drugs for Obesity, p. 753-755
• Holst JJ, Nat Metab 2024 (PMID 39160334) - GLP-1 physiology and incretin drug development
• Kokkorakis et al., Pharmacol Rev 2025 (PMID 39952695) - Emerging pharmacotherapies for obesity: systematic review
• Karakasis et al., Metabolism 2025 (PMID 39719170) - Body composition network meta-analysis
• Wharton et al., NEJM 2025 (PMID 40960239) - Orforglipron Phase 3 (ATTAIN-1)
• Deanfield et al., Lancet 2024 (PMID 39181597) - SELECT trial HF sub-analysis
• Qin et al., Endocrine 2024 (PMID 38850440) - Tirzepatide systematic review + SURMOUNT-2
• Katsi et al., Biomolecules 2025 (PMID 40563436) - Retatrutide review
• ADA 2026 Scientific Sessions - Weintraub MD, Docwire News (July 6, 2026)